Seeking to provide clarity to the pharmaceutical industry, the Office of Inspector General (OIG) has released a special advisory bulletin providing a regulatory framework for manufacturers selling prescription drugs direct-to-consumers (DTC). The guidance specifically addresses how the federal anti-kickback statute (AKS) applies to cash-paying patients, including those enrolled in federal healthcare programmes. For pharma leaders, this notice offers a roadmap for sustainable DTC models that bypass federal legal pitfalls. By connecting patients directly with manufacturer discount programs, the DTC model optimises patient affordability and streamlines access to essential therapies. Because the AKS is a criminal statute, the agency plans to continuously evaluate plans on a case-by-case basis based on the underlying intent of the parties involved.